Medical Pharmacology

Prof. Dr. Rezzan Gülhan

Doctor and researcher Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi İstanbul
Parkinson DiseaseEpilepsy, Absence
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Parkinson Disease 2 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Epilepsy, Absence 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Pharmacologysaglik.gov.trFrom source
  • InstitutionMarmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workParkinson DiseaseExtracted from 2 publications · Model version —From source
  • Publications31 publicationsEurope PMC, ORCID, OpenAlexFrom source
  • ORCID0000-0002-1519-3170ORCIDFrom source
  • Last synchronised5 November 2026 10:37https://marmaraeah.saglik.gov.tr/TR-1393577/doktorlarimiz.html#rezzan-gulhansaglik.gov.tr

Scientific work

Publications on Parkinson Disease

31 publications

  1. The effect of growth hormone on motor findings and dendrite morphology in an experimental Parkinson's disease model

    Anatomical science international, 2025

    DOI 10.1007/s12565-024-00790-6 PMID 39085683 2 citations (Europe PMC) Source: Europe PMC

  2. Pharmacotherapy of Neurodegenerative Diseases

    CRC Press eBooks, 2025

    DOI 10.1201/9781032676555-4 2 citations (OpenAlex) Source: ORCID

  3. Evaluation of isolated and combined effects of riluzole and sodium valproate in genetic absence epilepsy rats

    Marmara Medical Journal, 2025

    DOI 10.5472/marumj.1629028 1 citation (OpenAlex) Open-access full textSource: ORCID

  4. Effect of methylglyoxal on Parkinson's disease pathophysiology in the rotenone model

    Marmara Medical Journal, 2024

    DOI 10.5472/marumj.1480086 1 citation (OpenAlex) Open-access full textSource: ORCID

  5. Ethosuximide-loaded bismuth ferrite nanoparticles as a potential drug delivery system for the treatment of epilepsy disease

    Plos One, 2024

    DOI 10.1371/journal.pone.0305335 PMID 39312534 3 citations (Europe PMC) Open-access full textSource: ORCID

  6. Fabrication of ethosuximide loaded alginate/polyethylene oxide scaffolds for epilepsy research using 3D-printing method

    Frontiers in Bioengineering and Biotechnology, 2023

    DOI 10.3389/fbioe.2023.1244323 PMID 38107613 2 citations (Europe PMC) Open-access full textSource: ORCID

  7. Favipiravir Does Not Appear to Be a Major Teratogen: Case Series from Türkiye

    Journal of Gynecology Obstetrics and Human Reproduction, 2023

    DOI 10.1016/j.jogoh.2023.102693 PMID 37984519 4 citations (OpenAlex) Open-access full textSource: ORCID

  8. Favipiravir Does Not Appear to Be a Major Teratogen: Case Series from Türkiye

    Ssrn, 2023

    DOI 10.2139/ssrn.4443306 Open-access full textSource: Europe PMC

  9. Pharmacokinetic characterization of favipiravir in patients with COVID-19

    British Journal of Clinical Pharmacology, 2022

    DOI 10.1111/bcp.15227 PMID 35014080 21 citations (Europe PMC) Open-access full textSource: ORCID

  10. Duration of Ciprofloxacin Use Is Important in the Development of Abdominal Aortic Aneurysm in a Rat Model

    The Anatolian Journal of Cardiology, 2022

    DOI 10.5152/anatoljcardiol.2022.1939 PMID 35949127 5 citations (OpenAlex) Open-access full textSource: OpenAlex

View all 31 publications